Prevalence and incidence of the metabolic syndrome in the European Lacidipine Study on Atherosclerosis (ELSA) and its relation with carotid intima-media thickness

Journal of Hypertension

Volumn 25, Issue 12, 2007, Pages 2463-2470

  Zanchetti, Alberto ^a   Hennig, Micheal ^b   Baurecht, Hansjoerg ^c   Tang, Rong ^d   Cuspidi, Cesare ^e   Carugo, Stefano ^a   Mancia, Giuseppe ^e  

^a UNIVERSITY OF MILAN   (Italy)

^b Fresenius Biotech   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d WAKE FOREST SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF MILANO BICOCCA   (Italy)

Author keywords

Antihypertensive treatment; Atenolol; Carotid intima media thickness; Lacidipine; Metabolic syndrome

Indexed keywords

ATENOLOL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LACIDIPINE; TRIACYLGLYCEROL;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTERY INTIMA; ARTERY MEDIA; ARTICLE; BLOOD PRESSURE; BLOOD VESSEL WALL; BODY MASS; CAROTID ARTERY; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE COURSE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; INCIDENCE; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PREVALENCE; PRIORITY JOURNAL; WAIST CIRCUMFERENCE;

EID: 35848945483     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e3282f063d5     Document Type: Article

References (33)

1. Isoemaa B, Almgren P, Tuomi T, Forsen B, Nissen M, Taskinen MR, Groop L. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24:683-689.
2. Sattar N, Gaw A, Scherbakova O, O'Reilly DS, Haffner SM, Isles C, et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention study. Circulation 2003; 108:414-419.
3. Lindsay RS, Howard BV. Cardiovascular risk associated with the metabolic syndrome. Curr Diab Rep 2004; 4:63-68.
4. Schillaci G, Pirro M, Vaudo G, Gemelli F, Marchesi S, Porcellati C, Mannarino E. Prognostic value of the metabolic syndrome in essential hypertension. J Am Coll Cardiol 2004; 43:1817-1822.
5. Rutter MK, Meigs GB, Sullivan LM, D'Agostino RB, Wilson PWF. C-reactive protein, the metabolic syndrome and prediction of cardiovascular events in the Framingham offspring study. Circulation 2004; 110:380-385.
6. Malik S, Wong ND, Franklin SS, Kamath TV, L'Italien GJ, Pio JR, Williams GR. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease and all cause in United States adults. Circulation 2004; 110:1245-1250.
7. Hunt KJ, Resendez RG, Williams K, Haffner SM, Stern MP. National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study. Circulation 2004; 110:1251-1257.
8. Hu G, Qiao Q, Tuomilehto J, Balkau B, Borch-Johnsen K, Pyorala K, for the DECODE Study Group. Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in non diabetic European men and women. Arch Intern Med 2004; 164:1066-1076.
9. McNeill AM, Rosamond WD, Girman CJ, Golden SH, Schmidt MI, East HE, et al. The metabolic syndrome and 11-year risk of incident cardiovascular disease in the Atherosclerosis Risk in Communities Study. Diabetes Care 2005; 28:385-390.
10. Dekker JM, Girman C, Rhodes T, Nijpels G, Stehouher CD, Bouter LM, Heine RJ. Metabolic syndrome and 10-year cardiovascular disease risk in the Hoorn Study. Circulation 2005; 112:666-673.
11. Mancia G, Bombelli M, Corrao G, Facchetti R, Madotto F, Giannattasio C, et al. Metabolic syndrome in the Pressioni Arteriose Monitorate e Loro Associazioni (PAMELA) Study. Daily life blood pressure, cardiac damage, and prognosis. Hypertension 2007; 49:40-47.
12. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 287:356-359.
13. McKeown NM, Meigs JB, Liu S, Saltzman E, Wilson PW, Jacques PF. Carbohydrate nutrition, insulin resistance, and the prevalence of the metabolic syndrome in the Framingham Offspring Cohort. Diabetes Care 2004; 27:538-546.
14. Cameron AJ, Shaw JE, Zimmet PZ. The metabolic syndrome: prevalence in worldwide populations. Endocrinol Metab Clin N Am 2004; 33:351-375.
15. Muntner P, He J, Chen J, Fonseca V, Whelton PK. Prevalence of nontraditional cardiovascular disease risk factors among persons with impaired fasting glucose, impaired glucose tolerance, diabetes, and the metabolic syndrome: analysis of the Third National Health and Nutrition Examination Survey (NHANES III). Ann Epidemiol 2004; 14:686-695.
16. Ford ES, Abbasi F, Reaven GM. Prevalence of insulin resistance and the metabolic syndrome with alternative definitions of impaired fasting glucose. Atherosclerosis 2005; 181:143-148.
17. Cuspidi C, Meani S, Fusi V, Severgnini B, Valerio C, Catini E, et al. Metabolic syndrome and target organ damage in untreated essential hypertensives. J Hypertens 2004; 22:1991-1998.
18. Leoncini G, Ratto E, Viazzi F, Vaccaio V, Parodi D, Parodi A, et al. Metabolic syndrome is associated with early signs of organ damage in non diabetic, hypertensive patients. J Int Med 2005; 257:454-459.
19. Chinali M, Devereux RB, Howard BV, Roman MJ, Bella JN, Liu JE, et al. Comparison of cardiac structure and function in American Indians with and without the metabolic syndrome (the Strong Heart Study). Am J Cardiol 2004; 9:40-44.
20. Palaniappan L, Carnethon M, Fortmann SP. Association between microalbuminuria and the metabolic syndrome: NHANES III. Am J Hypertens 2003; 16:952-958.
21. Chen J, Muntner P, Hamm LL, Jones DW, Batuman V, Fonseca V, et al. The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med 2004; 140:167-174.
22. Scuteri A, Najjar SS, Muller DC, Andres R, Hougaku H, Metter EJ, Lakatta EG. Metabolic syndrome amplifies the age-associated increase in vascular thickness and stiffness. J Am Coll Cardiol 2004; 43:1388-1395.
23. Hedblad B, Nilsson P, Engstrom G, Berglund G, Janzon L. Insulin resistance in nondiabetic subjects is associated with increased incidence of myocardial infarction and death. Diabet Med 2002; 19:470-475.
24. Hulthe J, Wiklund O, Bondjers G, Wikstrand J. The metabolic syndrome, LDL particle size, and atherosclerosis: the Atherosclerosis and Insulin Resistance (AIR) study. Arterioscler Thromb Vasc Biol 2000; 20:2140-2147.
25. Mancia G, Grassi G, Zanchetti A. New-onset diabetes and antihypertensive drugs. J Hypertens 2006; 24:3-10.
26. Zanchetti A, Bond MG, Hennig M, Neiss A, Mancia G, Dal Palu C, et al. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation 2002; 106:2422-2427.
27. Zanchetti A, Bond MG, Hennig M, Tang R, Hollweck R, Mancia G, et al. Absolute and relative changes in carotid intima-media thickness and atherosclerotic plaques during long-term antihypertensive treatment: further results of the European Lacidipine Study on Atherosclerosis (ELSA). J Hypertens 2004; 22:1201-1212.
28. NNCEP. Third Report of the National Cholesterol Education Program (NNCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) Final report. Circulation 2002; 106:3143-3421.
29. Palaniappan L, Carnethon MR, Wang Y, Hanley AJ, Fortmann SP, Haffner SM, Wagenknecht L. Predictors of the incident metabolic syndrome in adults: the Insulin Resistance Atherosclerosis Study. Diabetes Care 2004; 27:788-793.
30. Lindholm LH, Persson M, Alaupovic P, Carlberg B, Svensson A, Samuelsson O. Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). J Hypertens 2003; 21:1563-1574.
31. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288:2981-2997.
32. Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, Messerli FH, et al. A calcium antagonist vs a noncalcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003; 290:2805-2816.
33. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363:2022-2031.